

Ichiro Kawada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6480151/publications.pdf>

Version: 2024-02-01

17
papers

600
citations

933264

10
h-index

940416

16
g-index

17
all docs

17
docs citations

17
times ranked

1093
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world clinical practice for advanced non-small-cell lung cancer in the very elderly: A retrospective multicenter analysis. <i>Clinical Lung Cancer</i> , 2022, 23, 532-541.	1.1	2
2	Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model. <i>Biochemical and Biophysical Research Communications</i> , 2021, 534, 1-7.	1.0	2
3	Eosinophilic annular erythema showing eosinophil cytolytic ETosis successfully treated with benralizumab. <i>Asia Pacific Allergy</i> , 2021, 11, e28.	0.6	7
4	Thymoma-associated T-cell immunodeficiency after radiotherapy: A case report. <i>Respiratory Medicine Case Reports</i> , 2021, 33, 101408.	0.2	1
5	Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. <i>Cancer Research</i> , 2021, 81, 3916-3929.	0.4	13
6	Unbiased, comprehensive analysis of Japanese health checkup data reveals a protective effect of light to moderate alcohol consumption on lung function. <i>Scientific Reports</i> , 2021, 11, 15954.	1.6	0
7	Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2489-2509.	1.8	52
8	Intracellular levels of reactive oxygen species correlate with ABT263 sensitivity in non-small cell lung cancer cells. <i>Cancer Science</i> , 2020, 111, 3793-3801.	1.7	4
9	IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 549-559.	1.5	34
10	Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1593-1601.	1.9	4
11	Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10025-10030.	3.3	41
12	Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations. <i>Lung Cancer</i> , 2019, 127, 146-152.	0.9	42
13	Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 740-750.	1.9	27
14	Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. <i>Cancer Research</i> , 2017, 77, 2078-2089.	0.4	126
15	Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer. <i>Molecular Cancer Research</i> , 2017, 15, 106-114.	1.5	54
16	Activation of EGFR Bypass Signaling by TGF β Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 162-171.	1.9	54
17	In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. <i>Oncotarget</i> , 2015, 6, 38789-38803.	0.8	137